ArticleJournal of the American College of Cardiology2023
Lipoprotein(a), Oxidized Phospholipids, and Coronary Artery Disease Severity and Outcomes.
Article in Journal of the American College of Cardiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00842868 (The CASABLANCA Study), which is not on this map. Cited by 60 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The CASABLANCA Study: Catheter Sampled Blood Archive in Cardiovascular Diseases. An Observational Biomarker Study
Who cites it
60 citing papers in PubMed, 2 syntheses or guidelines pooled it, 116 citations in OpenAlex.
- The Association of Lipoprotein(a) with Major Adverse Cardiovascular Events after Acute Myocardial Infarction: A Meta-Analysis of Cohort Studies.Reviews in cardiovascular medicine · 2025Pooled it
- Oxidized Phospholipids and Calcific Aortic Valvular Disease.Journal of the American College of Cardiology · 2024Pooled it
- The effects of colchicine on lipoprotein(a)- and oxidized phospholipid-associated cardiovascular disease risk.European journal of preventive cardiology · 2025Trial
- Olpasiran, Oxidized Phospholipids, and Systemic Inflammatory Biomarkers: Results From the OCEAN(a)-DOSE Trial.JAMA cardiology · 2025Trial
- Passive E06 IgG reduces lesional PC-OxPL and macrophage accumulation in cholesterol-fed LdlrAtherosclerosis plus · 2026Article
- The Roles of Lipoprotein(a) in Atherosclerosis - Minding the Knowledge Gaps.Current atherosclerosis reports · 2026Review
- Lipoprotein(a) Is Associated with Coronary Plaque Vulnerability and Compensatory Vascular Enlargement: An Intravascular Ultrasound Study.Journal of atherosclerosis and thrombosis · 2026Article
- Article
- The role of Lipoprotein(a) and oxidized phospholipids in modifying the effects of aspirin on major cardiovascular events and bleeding in the ASPirin in Reducing Events in the Elderly (ASPREE) randomized clinical trial: Statistical analysis plan.medRxiv : the preprint server for health sciences · 2026Article
- Biopsychosocial risk factors for Alzheimer's disease and related dementias in UK immigrants from the Middle East and North Africa (MENA).medRxiv : the preprint server for health sciences · 2026Article
- Predictive Value of Lipoprotein(a) Combined with the Suita Score for High-Risk Plaque in Japanese Patients.Journal of atherosclerosis and thrombosis · 2026Article
- Association of Elevated Lipoprotein(a) Levels with Major Adverse Cardiovascular Events in Non-Diabetic Patients with Acute Myocardial Infarction: A Cohort Study from Bosnia and Herzegovina.Medical sciences (Basel, Switzerland) · 2026Article
- Correlation between elevated Lp(a) levels and cardiovascular risk in coronary heart disease patients with different homocysteine concentrations.BMC cardiovascular disorders · 2026Article
- Serum ICAM-1 and VCAM-1 as markers of endothelial activation in ankylosing spondylitis and psoriatic arthritis: a cross-sectional study.BMC rheumatology · 2026Article
- A novel immune-isolation method for direct quantification of triglycerides associated with lipoprotein(a).Journal of lipid research · 2026Article
- Distribution of Lipoprotein(a) Levels and Clinical Associations in a Lebanese Adult Population: A Retrospective Observational Study.Journal of clinical medicine · 2026Article
- Lipoprotein(a) and Cardiovascular Disease: From Genetic Risk Factor to Therapeutic Target.Cells · 2026Review
- Oxidized phospholipids on plasminogen are associated with reduced platelet surface marker expression and intrinsic reactivity.Journal of thrombosis and thrombolysis · 2026Observational
- Efficacy and safety of lipoprotein(a)-targeted therapeutics: a systematic review and network meta-analysis.Frontiers in cardiovascular medicine · 2026Review
- Novel lipid parameters for predicting and interpreting the severity of coronary artery lesions in premature coronary artery disease.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
- Commented on by
Authors and funding
13 authors at 6 institutions in 1 country.
Funding
Abstract
backgroundLipoprotein(a) (Lp[a]) and oxidized phospholipids (OxPLs) are each independent risk factors for atherosclerotic cardiovascular disease. The extent to which Lp(a) and OxPLs predict coronary artery disease (CAD) severity and outcomes in a contemporary, statin-treated cohort is not well established.
objectivesThis study sought to evaluate the relationships between Lp(a) particle concentration and OxPLs associated with apolipoprotein B (OxPL-apoB) or apolipoprotein(a) (OxPL-apo[a]) with angiographic CAD and cardiovascular outcomes.
methodsAmong 1,098 participants referred for coronary angiography in the CASABLANCA (Catheter Sampled Blood Archive in Cardiovascular Diseases) study, Lp(a), OxPL-apoB, and OxPL-apo(a) were measured. Logistic regression estimated the risk of multivessel coronary stenoses by Lp(a)-related biomarker level. Cox proportional hazards regression estimated the risk of major adverse cardiovascular events (MACEs) (coronary revascularization, nonfatal myocardial infarction, nonfatal stroke, and cardiovascular death) in follow-up.
resultsMedian Lp(a) was 26.45 nmol/L (IQR: 11.39-89.49 nmol/L). Lp(a), OxPL-apoB, and OxPL-apo(a) were highly correlated (Spearman R ≥0.91 for all pairwise combinations). Lp(a) and OxPL-apoB were associated with multivessel CAD. Odds of multivessel CAD per doubling of Lp(a), OxPL-apoB, and OxPL-apo(a) were 1.10 (95% CI: 1.03-1.18; P = 0.006), 1.18 (95% CI: 1.03-1.34; P = 0.01), and 1.07 (95% CI: 0.99-1.16; P = 0.07), respectively. All biomarkers were associated with cardiovascular events. HRs for MACE per doubling of Lp(a), OxPL-apoB, and OxPL-apo(a) were 1.08 (95% CI: 1.03-1.14; P = 0.001), 1.15 (95% CI: 1.05-1.26; P = 0.004), and 1.07 (95% CI: 1.01-1.14; P = 0.02), respectively.
conclusionsIn patients undergoing coronary angiography, Lp(a) and OxPL-apoB are associated with multivessel CAD. Lp(a), OxPL-apoB, and OxPL-apo(a) are associated with incident cardiovascular events. (Catheter Sampled Blood Archive in Cardiovascular Diseases [CASABLANCA]; NCT00842868).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.